Advertisement
DHR vs RGEN
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Repligen Corporation (RGEN) Stock Comparison
Key Takeaways
- Danaher Corporation (DHR) operates as a diversified life sciences and diagnostics company with broad exposure across biotechnology, life sciences, and diagnostics segments.
- Repligen Corporation (RGEN) focuses primarily on bioprocessing technologies and has delivered stronger recent momentum with double-digit organic revenue growth.
- In recent market activity, DHR shares have shown modest gains amid dividend declarations and acquisition integration, while RGEN has outperformed with notable year-to-date advances.
- Sector exposure differs markedly: DHR offers diversified stability, whereas RGEN provides concentrated growth tied to bioprocessing demand and strategic acquisitions.
- Market sentiment reflects DHR navigating slower near-term organic growth expectations, contrasted with RGEN benefiting from raised guidance and positive analyst coverage.
- Relative performance highlights trade-offs between DHR’s scale and resilience versus RGEN’s higher-growth profile in a specialized niche.
Introduction
Investors and traders seeking to compare established players in the life sciences sector often examine Danaher Corporation (DHR) and Repligen Corporation (RGEN) for their distinct approaches to growth and market positioning. This comparison appeals to those evaluating relative performance, sector exposure, and momentum in biotechnology-related equities amid evolving demand for bioprocessing and diagnostic tools. Both companies operate within overlapping industry dynamics yet differ in scale, diversification, and recent trajectory, providing a useful lens for assessing opportunities in healthcare innovation and supply chain resilience.
Danaher Corporation (DHR) Overview and Recent Performance
Danaher Corporation (DHR) delivers a broad portfolio spanning biotechnology, life sciences, and diagnostics, serving customers in research, clinical, and industrial settings. Recent market activity has featured steady execution following second-quarter results that showed revenue expansion and margin improvement, supported by the earlier completion of the Masimo acquisition. Share price behavior in recent weeks has reflected modest advances alongside a quarterly dividend declaration of $0.40 per share. Influences on sentiment include core sales growth trends excluding respiratory testing and ongoing integration of acquired businesses, with analysts noting resilience in the Danaher Business System amid deferred revenue considerations.
Repligen Corporation (RGEN) Overview and Recent Performance
Repligen Corporation (RGEN) specializes in bioprocessing technologies, including proteins, analytics, and filtration solutions critical to biologic drug manufacturing. Recent market activity has highlighted robust organic revenue growth and an upgraded full-year outlook following second-quarter results that exceeded expectations. Share price behavior in recent weeks has demonstrated resilience with notable advances over the prior year, bolstered by the pending BioLife Solutions acquisition and favorable analyst commentary. Influences on sentiment include sustained demand in bioprocessing and exposure to emerging modalities such as vaccines, positioning the company for continued expansion in a high-growth niche.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots designed for copy trading across stocks, ETFs, and crypto. Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, yet only the strongest performers suited to prevailing market conditions earn placement in this Trending AI Robots section. The platform currently features its best AI trending bots (34) selected out of 316 total, with bots differentiated by trading styles, strategies, timeframes, performance metrics, and specific ticker sets. Users can explore options based on volatility tolerance, analysis type, or asset class. For those interested in automated strategies, visit the Trending AI Robots page to review available plans and performance details.
Head-to-Head Comparison
Danaher Corporation (DHR) emphasizes scale and diversification across multiple life sciences verticals, offering stability through recurring revenue streams in consumables and services, while Repligen Corporation (RGEN) concentrates on high-growth bioprocessing applications with greater sensitivity to industry capital spending cycles. Growth drivers contrast sharply: DHR benefits from broad end-market recovery and acquisition synergies, whereas RGEN leverages innovation in protein and analytics platforms plus portfolio expansion via deals. Recent momentum favors RGEN’s double-digit organic gains against DHR’s more measured core expansion. Risk factors include DHR’s exposure to integration costs and deferred revenue timing versus RGEN’s higher valuation multiples and acquisition execution. Sector exposure places both in life sciences, yet RGEN’s pure-play profile amplifies upside in biomanufacturing demand compared with DHR’s balanced but slower-reacting segments. Market sentiment currently tilts toward RGEN’s raised guidance amid analyst upgrades, while DHR contends with tempered near-term outlook narratives.
Tickeron AI Verdict
Based on observable factors such as trend consistency, growth catalysts, and relative positioning, Tickeron’s AI would currently assign a higher probability of favorable momentum to Repligen Corporation (RGEN) over Danaher Corporation (DHR). RGEN’s stronger recent organic performance, raised guidance, and concentrated bioprocessing exposure align with sustained demand trends, though both equities carry sector-specific risks that warrant ongoing monitoring of order patterns and macroeconomic influences.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and RGEN is a Hold.
DHR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 77 | 88 | |
PRICE GROWTH RATING 1..100 | 45 | 38 | |
P/E GROWTH RATING 1..100 | 42 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for RGEN (86) in the Biotechnology industry. This means that DHR’s stock grew significantly faster than RGEN’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as RGEN (88) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's Price Growth Rating (38) in the Biotechnology industry is in the same range as DHR (45) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to DHR’s over the last 12 months.
DHR's P/E Growth Rating (42) in the Medical Specialties industry is somewhat better than the same rating for RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew somewhat faster than RGEN’s over the last 12 months.
| DHR | RGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 48% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 73% |
| Advances ODDS (%) | 5 days ago 54% | 4 days ago 73% |
| Declines ODDS (%) | 2 days ago 60% | 2 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 52% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 60% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 2 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 6 bearish.
- RGEN’s TA Score: 2 bullish, 6 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -4.48% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -4.21% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.92%. For the same industry, the average monthly price growth was +3.80%, and the average quarterly price growth was +46.57%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.16%. For the same industry, the average monthly price growth was -5.16%, and the average quarterly price growth was +14.10%.
Reported Earning Dates
DHR is expected to report earnings on Oct 21, 2026.
RGEN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (-2.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-2.16% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +1.09% | ||
| TMO - DHR | 73% Closely correlated | +0.35% | ||
| RGEN - DHR | 68% Closely correlated | +2.52% | ||
| BIO - DHR | 64% Loosely correlated | +3.82% | ||
| A - DHR | 60% Loosely correlated | +0.66% | ||
| BRKR - DHR | 58% Loosely correlated | +2.10% | ||
More | ||||
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | +2.52% | ||
| DHR - RGEN | 67% Closely correlated | +1.09% | ||
| A - RGEN | 65% Loosely correlated | +0.66% | ||
| BIO - RGEN | 60% Loosely correlated | +3.82% | ||
| MTD - RGEN | 59% Loosely correlated | +0.34% | ||
| TMO - RGEN | 58% Loosely correlated | +0.35% | ||
More | ||||